Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07006727 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

A Phase 1 study of Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
116
Enrollment target
5
Study locations

NCT07006727 is a Phase 1 study of Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 116 participants, below the 255-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target (55% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07006727, a Phase 1 study of Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
116 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.

Conditions Studied

Small Cell Lung Carcinoma Large Cell Neuroendocrine Carcinoma of the Lung Neuroendocrine Prostate Cancer Gastroenteropancreatic Neuroendocrine Carcinoma

Interventions

  • DRUG 225Ac-ETN029
  • DRUG 111In-ETN029

Study Locations (5)

Iowa

  • University Of Iowa - Iowa City

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • Corewell Health William Beaum Hosp - Royal Oak

Quebec

  • Novartis Investigative Site - Montreal

Korea

  • Novartis Investigative Site - Seoul

Trial Details

FieldValue
Enrollment Target 116 participants
Start Date 2025-10-16
Est. Completion 2031-06-17
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07006727

The ClinicalTrials.gov registry entry for NCT07006727 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target (55% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which 225Ac-ETN029 is the first listed.

NCT07006727 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Iowa, Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT07006727 about?

NCT07006727 is a clinical study titled "Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.

What is the current status of trial NCT07006727?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2025-10-16. Estimated completion is 2031-06-17.

What conditions does trial NCT07006727 study?

This clinical trial studies the following conditions: Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma.

What interventions are being tested in trial NCT07006727?

The interventions under investigation include: 225Ac-ETN029 (DRUG), 111In-ETN029 (DRUG).

Who is sponsoring clinical trial NCT07006727?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07006727 being conducted?

This trial has 5 study locations across Iowa, Massachusetts, Michigan, Quebec, Korea. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small Cell Lung Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small Cell Lung Carcinoma

All registered trials for this condition

Large Cell Neuroendocrine Carcinoma of the Lung

All registered trials for this condition

Iowa

All trials with a study site in Iowa

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.